CORRECTED: PTAB Axes Patent After Purdue Ch. 11 Delay
The Patent Trial and Appeal Board has invalidated a Purdue Pharma patent for an opioid with an abuse deterrent, faulting the patent description and rejecting Purdue's argument that the board took...To view the full article, register now.
Already a subscriber? Click here to view full article